News
NGEN
1.960
+4.81%
0.090
Weekly Report: what happened at NGEN last week (0622-0626)?
Weekly Report · 18h ago
H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)
TipRanks · 4d ago
Weekly Report: what happened at NGEN last week (0615-0619)?
Weekly Report · 06/22 09:06
Weekly Report: what happened at NGEN last week (0608-0612)?
Weekly Report · 06/15 09:06
NervGen rises as TD Cowen issues new Buy on lead asset
Seeking Alpha · 06/11 17:45
H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)
TipRanks · 06/11 13:46
NERVGEN PHARMA CORP <NGEN.O>: TD COWEN INITIATES COVERAGE WITH BUY RATING
Reuters · 06/11 10:06
NervGen Pharma initiated with a Buy at TD Cowen
TipRanks · 06/11 09:51
Weekly Report: what happened at NGEN last week (0601-0605)?
Weekly Report · 06/08 09:05
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 06/03 21:07
NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program
TipRanks · 06/01 23:16
NervGen prices 24,000,000-share offering with warrants at US$2.5, targets US$60 million gross proceeds
PUBT · 06/01 21:30
Weekly Report: what happened at NGEN last week (0525-0529)?
Weekly Report · 06/01 09:06
Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors
TipRanks · 05/29 16:32
NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3
TipRanks · 05/26 21:17
NervGen Pharma Increases Mixed Shelf Offering From $150M To $250M
Benzinga · 05/26 13:31
NervGen Pharma files $250M mixed securities shelf
TipRanks · 05/26 13:28
NERVGEN PHARMA INCREASES MIXED SHELF OFFERING TO $250 MLN FROM $150 MLN - SEC FILING
Reuters · 05/26 13:28
Why Is NervGen Pharma Stock Gaining Tuesday?
Benzinga · 05/26 12:33
NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291
TipRanks · 05/26 11:39
More
Webull provides a variety of real-time NGEN stock news. You can receive the latest news about Nervgen Pharma Corp through multiple platforms. This information may help you make smarter investment decisions.
About NGEN
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.